News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
VUCC PTY LTD Announces Lodgement in Germany of Patent for Treatment of Type I Diabetes
March 3, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH & MELBOURNE, Australia--(BUSINESS WIRE)--VUCCC P/L is pleased to announce that it has filed for patent protection of its ground breaking new treatment regimen for Type 1 'insulin-dependent' diabetes, through the European Patent Office.
Twitter
LinkedIn
Facebook
Email
Print
Asia
Europe
Australia
MORE ON THIS TOPIC
China
Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
September 24, 2026
·
1 min read
·
Tristan Manalac
Job Trends
Growth mode: 3 biotechs that are staffing up after series B raises
September 24, 2026
·
3 min read
·
Angela Gabriel
Deals
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
September 23, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
September 21, 2026
·
2 min read
·
Nick Paul Taylor